Jpmorgan Chase & CO Atreca, Inc. Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.56 - $3.25 $19,003 - $39,591	-12,182 Reduced 99.81%	23 $0
Q1 2022 May 11, 2022	SELL	$1.61 - $5.2 $314,642 - $1.02 Million	-195,430 Reduced 94.12%	12,205 $39,000
Q4 2021 Feb 10, 2022	BUY	$2.87 - $6.29 $137,478 - $301,303	47,902 Added 29.99%	207,635 $629,000
Q3 2021 Nov 12, 2021	BUY	$4.91 - $9.07 $784,289 - $1.45 Million	159,733 New	159,733 $995,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.